The number of domestic pharmaceutical companies acquiring domestic copyrights of original drugs has been increasing recently. This is a case in which domestic copyrights have also changed as most original developers sold global copyrights as part of restructuring. Jeil announced on the 8th that it will exclusively supply Bonviva and Bonviva plus, treatments for osteoporosis, in Korea. Bonviva originally entered the domestic market with permission from Roche, a multinational pharmaceutical company. As global copyright was transferred to British pharmaceutical company Aetna Pharma in 2017, domestic copyrights are also changing. Since 2015, Handok has been selling and obtaining permission rights, but it has recently been